BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36600652)

  • 1. SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response.
    Tanagala KKK; Morin-Baxter J; Carvajal R; Cheema M; Dubey S; Nakagawa H; Yoon A; Cheng YL; Taylor A; Nickerson J; Mintz A; Momen-Heravi F
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140.
    Ghiboub M; Koster J; Craggs PD; Li Yim AYF; Shillings A; Hutchinson S; Bingham RP; Gatfield K; Hageman IL; Yao G; O'Keefe HP; Coffin A; Patel A; Sloan LA; Mitchell DJ; Hayhow TG; Lunven L; Watson RJ; Blunt CE; Harrison LA; Bruton G; Kumar U; Hamer N; Spaull JR; Zwijnenburg DA; Welting O; Hakvoort TBM; Te Velde AA; van Limbergen J; Henneman P; Prinjha RK; de Winther MPJ; Harker NR; Tough DF; de Jonge WJ
    BMC Biol; 2022 Aug; 20(1):182. PubMed ID: 35986286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. m
    Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM
    EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTLA-4 blockade induces tumor pyroptosis via CD8
    Wang S; Wu ZZ; Zhu SW; Wan SC; Zhang MJ; Zhang BX; Yang QC; Xiao Y; Li H; Mao L; Wang ZY; Gutkind JS; Sun ZJ
    Mol Ther; 2023 Jul; 31(7):2154-2168. PubMed ID: 36869589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siglec-9
    Wang Y; He M; Zhang C; Cao K; Zhang G; Yang M; Huang Y; Jiang W; Liu H
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors.
    Tao Q; Liu N; Wu J; Chen J; Chen X; Peng C
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.
    Leibowitz MS; Andrade Filho PA; Ferrone S; Ferris RL
    Cancer Immunol Immunother; 2011 Apr; 60(4):525-35. PubMed ID: 21207025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of
    Zhang P; Zhao Y; Xia X; Mei S; Huang Y; Zhu Y; Yu S; Chen X
    Oncoimmunology; 2023; 12(1):2203073. PubMed ID: 37089448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
    Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment.
    Lin W; Luo Y; Wu J; Zhang H; Jin G; Guo C; Zhou H; Liang H; Xu X
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.
    Dai X; Lu L; Deng S; Meng J; Wan C; Huang J; Sun Y; Hu Y; Wu B; Wu G; Lovell JF; Jin H; Yang K
    Theranostics; 2020; 10(20):9332-9347. PubMed ID: 32802195
    [No Abstract]   [Full Text] [Related]  

  • 14. ZEB1 transcription factor promotes immune escape in melanoma.
    Plaschka M; Benboubker V; Grimont M; Berthet J; Tonon L; Lopez J; Le-Bouar M; Balme B; Tondeur G; de la Fouchardière A; Larue L; Puisieux A; Grinberg-Bleyer Y; Bendriss-Vermare N; Dubois B; Caux C; Dalle S; Caramel J
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8
    Ma S; Sun B; Duan S; Han J; Barr T; Zhang J; Bissonnette MB; Kortylewski M; He C; Chen J; Caligiuri MA; Yu J
    Nat Immunol; 2023 Feb; 24(2):255-266. PubMed ID: 36658237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.
    Zheng X; Luo Y; Xiong Y; Liu X; Zeng C; Lu X; Wang X; Cheng Y; Wang S; Lan H; Wang K; Weng Z; Bi W; Gan X; Jia X; Wang L; Wang Y
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes.
    Ardighieri L; Missale F; Bugatti M; Gatta LB; Pezzali I; Monti M; Gottardi S; Zanotti L; Bignotti E; Ravaggi A; Tognon G; Odicino F; Calza S; Missolo-Koussou Y; Ries CH; Helft J; Vermi W
    Front Immunol; 2021; 12():690201. PubMed ID: 34220848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma.
    Ryan N; Anderson K; Volpedo G; Hamza O; Varikuti S; Satoskar AR; Oghumu S
    Int J Cancer; 2020 Mar; 146(6):1717-1729. PubMed ID: 31709529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.